Status:

COMPLETED

The ImageKids Study: Developing the pMEDIC and the PICMI

Lead Sponsor:

Shaare Zedek Medical Center

Collaborating Sponsors:

Children's Hospital of Eastern Ontario

McMaster Children's Hospital

Conditions:

Crohn's Disease

Eligibility:

All Genders

5-18 years

Phase:

NA

Brief Summary

The overall objectives of this study are to develop two indices capable of measuring intestinal damage, and, separately, inflammatory disease activity in Pediatric Crohn's disease by means of Magnetic...

Detailed Description

The PICMI Score and the pMEDIC are aimed to be discriminative (at one point in time), evaluative (measuring damage progression over time) and predictive. The indices will be used as endpoint measures ...

Eligibility Criteria

Inclusion

  • Children (under 18 years of age) with established diagnosis of CD involving any location by the presence of accepted clinical, radiologic, endoscopic and histologic criteria (33, 34).
  • Enrolment at the time of performing ileocolonoscopy and esophageal-gastroduodenoscopy (EGD) as part of clinical care for any reason.
  • Children will be enrolled at any phase of the disease (at diagnosis and thereafter as required clinically). In order to ensure enough subjects with intestinal damage and since damage is progressing over time, enrolment will be stratified based on disease duration. Enrolment for each stratum of disease duration will be closed after reaching the expected sample size.
  • 20% of enrolled children will be within 3 months of diagnosis.
  • 20% of children will be between 3 months and 2 years.
  • 20% will be 2.01 to 3 years
  • 40% will have disease duration over 3-years.
  • Children may be enrolled in any disease activity state (PCDAI 0-100).

Exclusion

  • Young children requiring anesthesia for lack of cooperation will be excluded (since the enteric contrast cannot be administered during the 2 hours before anesthesia and it is crucial that the contrast be given just prior the test).
  • For the first 120 children only, subjects not expected to be available for 18 month follow-up, will be excluded (the last 120 subjects may be enrolled as they are not followed longitudinally).

Key Trial Info

Start Date :

January 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2017

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT01881490

Start Date

January 1 2013

End Date

March 1 2017

Last Update

May 1 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shaare Zedek Medical Center

Jerusalem, Israel